Journal article icon

Journal article

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.

Abstract:

IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported recently in AIDS-related Kaposi's sarcoma, a tumour of endothelial cell origin. The high vascularity and responsiveness to immunotherapy of renal cell carcinoma (RCC) makes such a tumour a potential target for IM862. In all, 25 patients were accrued in a prospective phase II trial using a standard two-step design. The main inclusion cr...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/sj.bjc.6602126

Authors


Journal:
British journal of cancer More from this journal
Volume:
91
Issue:
9
Pages:
1645-1650
Publication date:
2004-11-01
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Language:
English
Keywords:
Pubs id:
pubs:125327
UUID:
uuid:e76394e1-6375-4c10-a60f-ec216714b7f1
Local pid:
pubs:125327
Source identifiers:
125327
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP